Focus: Merit Medical is a public medical device company with $1.3B in revenue serving multiple therapeutic areas including cardiovascular, oncology, nephrology, ophthalmology, and neurology. The 5,000+ employee organization manufactures specialized interventional and surgical devices across a diversified portfolio.
Profile data last refreshed 18h ago · AI intelligence enriched 6d ago
Hot — 230 jobs added in 30d
Net +163 (230 new, 67 removed). Aggressive expansion phase.
Merit Medical is a stable, cash-generative device company suited for careers in commercialization and manufacturing operations, but offers limited exposure to clinical development and early-stage innovation.
Help build intelligence for Merit Medical
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Merit Medical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Medical & Pharmaceutical Dynamic Sealing Solutions Market - openPR.com
Medical & Pharmaceutical Dynamic Sealing Solutions Market openPR.com
Miller Investment Trust's Market Neutral Income Fund Reports $360M in Assets with Top Holdings in Merit, Nutanix, and Ascendis - Kalkine Media
Miller Investment Trust's Market Neutral Income Fund Reports $360M in Assets with Top Holdings in Merit, Nutanix, and Ascendis Kalkine Media
Medical Supplies Market worth $248.03 billion by 2031 - Exclusive Report by MarketsandMarkets™ - PR Newswire UK
Medical Supplies Market worth $248.03 billion by 2031 - Exclusive Report by MarketsandMarkets™ PR Newswire UK
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) The Manila Times
Here's Why You Should Add Merit Medical Stock to Your Portfolio Now - TradingView
Here's Why You Should Add Merit Medical Stock to Your Portfolio Now TradingView
Analysts Conflicted on These Healthcare Names: Axsome Therapeutics (AXSM), BioMarin Pharmaceutical (BMRN) and Envista Holdings (NVST) - theglobeandmail.com
Analysts Conflicted on These Healthcare Names: Axsome Therapeutics (AXSM), BioMarin Pharmaceutical (BMRN) and Envista Holdings (NVST) theglobeandmail.com
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Patency rates following treatment with the WRAPSODY™ Cell-Impermeable Endoprosthesis for recalcitrant renal access circuit dysfunction: Results from a tertiary Australian centre.
Objective Performance Goals Based on a Systematic Review and Meta-Analysis of Clinical Outcomes for Bare-Metal Stents and Percutaneous Transluminal Angioplasty for Hemodialysis-Related Central Venous Obstruction.
Showing 5 of 7 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo